Company Description
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix.
It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020.
AVITA Medical, Inc. is headquartered in Valencia, California.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 207 |
| CEO | James Corbett |
Contact Details
Address: 28159 Avenue Stanford, Suite 220 Valencia, California 91355 United States | |
| Phone | 661 367 9170 |
| Website | avitamedical.com |
Stock Details
| Ticker Symbol | RCEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001762303 |
| CUSIP Number | 05380C102 |
| ISIN Number | US05380C1027 |
| Employer ID | 20-2578762 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James M. Corbett | Chief Executive Officer, President and Executive Director |
| David O'Toole | Chief Financial Officer |
| David Fencil | Senior Vice President of Global Operations |
| Dr. Katie Bush Ph.D. | Senior Vice President of Scientific and Medical Affairs |
| Jessica Ekeberg | Investor Relations Executive |
| Nicole Linda Kelsey | Chief Legal and Compliance Officer and Corporate Secretary |
| Debbie Garner | Senior Vice President of Global Marketing and Strategy |
| Rob Hall | Senior Vice President of Human Resources |
| Dr. Niraj Doshi J.D., P.M.P., Ph.D. | Senior Vice President of Product Development and Program Management |
| Ron Lagerquist | Senior Vice President of Quality Assurance and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | 424B5 | Filing |
| Feb 13, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 8-K | Current Report |
| Jan 7, 2025 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 8-K | Current Report |